StreetInsider.com News Articles

Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer

Sat, 24 Oct 2026 07:00:00 -0400

Phase 1/2 study will evaluate INCB161734 plus petosemtamab and standard-of-care chemotherapy in first-line KRAS G12D-mutated metastatic colorectal cancer (mCRC)

WILMINGTON, Del. & COPENHAGEN, Denmark--(BUSINESS WIRE)-- Incyte (Nasdaq:INCY) and Genmab A/S (Nasdaq:GMAB) today announced a clinical trial collaboration to evaluate INCB161734, Incyte’s investigational, potent and selective KRAS G12D inhibitor, in combination with petosemtamab, Genmab’s investigational IgG1-bispecific antibody targeting the epidermal growth factor receptor (EGFR) and leucine-rich repeat containing G-protein-coupled receptor 5 (LGR5), and standard-of-care chemotherapy as a first-line treatment for patients with metastatic colorectal cancer harboring KRAS G12D mutation, an area with substantial unmet medical need.

“Metastatic colorectal cancer

Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer

Sat, 24 Oct 2026 07:00:00 -0400

Phase 1/2 study will evaluate INCB161734 plus petosemtamab and standard-of-care chemotherapy in first-line KRAS G12D-mutated metastatic colorectal cancer (mCRC)

“Metastatic colorectal cancer

Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer

Sat, 24 Oct 2026 07:00:00 -0400

Phase 1/2 study will evaluate INCB161734 plus petosemtamab and standard-of-care chemotherapy in first-line KRAS G12D-mutated metastatic colorectal cancer (mCRC)

“Metastatic colorectal cancer

Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer

Sat, 24 Oct 2026 07:00:00 -0400

Phase 1/2 study will evaluate INCB161734 plus petosemtamab and standard-of-care chemotherapy in first-line KRAS G12D-mutated metastatic colorectal cancer (mCRC)

“Metastatic colorectal cancer

Incyte (INCY) PT Raised to $140 at TD Cowen

Wed, 21 Oct 2026 08:12:07 -0400

TD Cowen analyst Tara Bancroft raised the price target on Incyte (NASDAQ: INCY) to $140.00 (from $138.00) while maintaining a Buy rating.

Morgan Stanley Assumes Incyte (INCY) at Equalweight

Tue, 20 Oct 2026 03:08:46 -0400

(Updated - October 20, 2026 3:08 AM EDT)

Morgan Stanley analyst Chris Yu assumes coverage on Incyte (NASDAQ: INCY) with a Equalweight rating and a price target of $119.00.

The analyst comments: “We are Equal-weight on INCY with a $119 PT, as focus remains on growing through the Jakafi LOE. Jakafi, which made up 69% of total revenue in 2025, is expected to lose exclusivity in Dec. 2028. Through growing the ex-Jakafi business and maturing the pipeline, INCY's overall strategy is centered on "shortening and shallowing the post-LOE trough." In 2027, INCY expects to provide a framework for how to think about

Morgan Stanley Assumes Incyte (INCY) at Equalweight

Tue, 20 Oct 2026 03:08:46 -0400

(Updated - October 20, 2026 3:08 AM EDT)

Morgan Stanley analyst Chris Yu assumes coverage on Incyte (NASDAQ: INCY) with a Equalweight rating and a price target of $119.00.

Form 4 INCYTE CORP For: Oct 15 Filed by: CAGNONI PABLO J

Mon, 19 Oct 2026 16:38:00 -0400

si-local-file:///var/storage/secattach/20261019/27204416.html

Incyte to Highlight Key Oncology Data Presentations at the European Society for Medical Oncology (ESMO) Congress 2026

Sun, 18 Oct 2026 18:05:00 -0400

Four rapid oral presentations at ESMO will feature new data for INCB161734, a KRAS G12D inhibitor, and INCA338901, a TGFβR2×PD-1 bispecific antibody

Both investigational therapies are being evaluated in ongoing Phase 3 programs

Incyte will host an investor event and webcast on Monday, October 26, 2026 from 7:30 – 9:00 CET / 2:30 – 4:00 p.m. ET

WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte (Nasdaq:INCY) today announced that it will present new data from its oncology portfolio during the European Society of Medical Oncology (ESMO) Congress 2026, being held October 23 - 27, 2026, in Madrid.

“The data being presented at

Incyte to Highlight Key Oncology Data Presentations at the European Society for Medical Oncology (ESMO) Congress 2026

Sun, 18 Oct 2026 18:05:00 -0400

Four rapid oral presentations at ESMO will feature new data for INCB161734, a KRAS G12D inhibitor, and INCA338901, a TGFβR2×PD-1 bispecific antibody

Both investigational therapies are being evaluated in ongoing Phase 3 programs

Incyte will host an investor event and webcast on Monday, October 26, 2026 from 7:30 – 9:00 CET / 2:30 – 4:00 p.m. ET

“The data being presented at

H.C. Wainwright Reiterates Buy Rating on Incyte (INCY)

Fri, 16 Oct 2026 06:49:47 -0400

H.C. Wainwright analyst Mitchell S. Kapoor reiterated a Buy rating and $152.00 price target on Incyte (NASDAQ: INCY).

The analyst commented: "Verastem’s chemo-free disease control supports the rationale for continuing Incyte’s ’734 after chemo reduction. On October 14, Verastem (VSTM; Maldonado; Buy) reported 67% six-month PFS and nine confirmed responses among 22 previously treated KRAS G12D-mutant pancreatic ductal adenocarcinoma (PDAC) patients receiving VS-7375 900 mg daily as monotherapy, representing a 41% confirmed ORR at 6.4 months median follow-up. Patients had received a median of two prior treatment lines. Like VS-7375, Incyte’s INCB161734 (’734) selectively inhibits both ON- and OFF-state KRAS G12D.

Form 144 INCYTE CORP Filed by: CAGNONI PABLO J

Thu, 15 Oct 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20261015/27193267.html

Incyte (INCY) PT Raised to $115 at Truist Securities

Wed, 14 Oct 2026 07:00:04 -0400

Truist Securities analyst Srikripa Devarakonda raised the price target on Incyte (NASDAQ: INCY) to $115.00 (from $105.00) while maintaining a Hold rating.

H.C. Wainwright Reiterates Buy Rating on Incyte (INCY)

Tue, 13 Oct 2026 06:46:58 -0400

H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating and $152.00 price target on Incyte (NASDAQ: INCY).

The analyst commented: "Newly released FDA documents reveal meaningful G12D response gap, strengthening case for Incyte's '734 ahead of ESMO. On October 8, FDA released its detailed regulatory review supporting the August approval of Revolution Medicines' Rasonque (daraxonrasib). Our review uncovered a notable difference beneath the pooled RASolute 302 results: confirmed response was 24% in KRAS G12D pancreatic ductal adenocarcinoma (PDAC; 23/95 patients) vs. 50% in G12V (47/94), despite comparable PFS benefit (HR 0.48 vs. 0.54). G12D accounts for ~40% of PDAC and represents

Incyte to Report Third Quarter Financial Results

Thu, 08 Oct 2026 08:00:00 -0400

WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte (Nasdaq:INCY) announced today that it has scheduled its third quarter financial results conference call and webcast for 8:00 a.m. ET on Thursday, October 29, 2026.

The schedule for the press release and conference call/webcast is as follows:

Q3 2026 Press Release: October 29, 2026, at 7:00 a.m. ET
Q3 2026 Conference Call: October 29, 2026, at 8:00 a.m. ET
Domestic Dial-In Number: 877-407-3042
International Dial-In Number: 201-389-0864
Conference ID Number: 13763051

If you are unable to participate, a replay of the conference will be available for thirty days. The replay dial-in number for the U.S. is 877-660-6853 and the

Incyte to Report Third Quarter Financial Results

Thu, 08 Oct 2026 08:00:00 -0400

The schedule for the press release and conference call/webcast is as follows:

Q3 2026 Press Release: October 29, 2026, at 7:00 a.m. ET
Q3 2026 Conference Call: October 29, 2026, at 8:00 a.m. ET
Domestic Dial-In Number: 877-407-3042
International Dial-In Number: 201-389-0864
Conference ID Number: 13763051

If you are unable to participate, a replay of the conference will be available for thirty days. The replay dial-in number for the U.S. is 877-660-6853 and the

Knight Therapeutics Announces Regulatory Approval of NIKTIMVO® in Brazil

Tue, 06 Oct 2026 07:35:00 -0400

MONTREAL, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. ("Knight") (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today it has received expedited regulatory approval under ANVISA’s rare disease pathway for NIKTIMVO® (axatilimab), for the treatment of chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patients 6 years and older weighing at least 40 kg.1

“For patients living with chronic graft-versus-host disease who have exhausted two prior lines of therapy, access to a new treatment option can be life-changing. NIKTIMVO® offers a first-in-class

Knight Therapeutics Announces Regulatory Approval of NIKTIMVO® in Brazil

Tue, 06 Oct 2026 07:35:00 -0400

“For patients living with chronic graft-versus-host disease who have exhausted two prior lines of therapy, access to a new treatment option can be life-changing. NIKTIMVO® offers a first-in-class

Knight Therapeutics Announces Regulatory Approval of NIKTIMVO® in Brazil

Tue, 06 Oct 2026 07:35:00 -0400

“For patients living with chronic graft-versus-host disease who have exhausted two prior lines of therapy, access to a new treatment option can be life-changing. NIKTIMVO® offers a first-in-class

Knight Therapeutics Announces Regulatory Approval of NIKTIMVO® in Brazil

Tue, 06 Oct 2026 07:35:00 -0400

“For patients living with chronic graft-versus-host disease who have exhausted two prior lines of therapy, access to a new treatment option can be life-changing. NIKTIMVO® offers a first-in-class

Form 4 INCYTE CORP For: Oct 01 Filed by: Heeson Lee

Mon, 05 Oct 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20261005/27148610.html

Incyte (INCY) PT Raised to $127 at UBS, Neutral Rating Maintained

Mon, 05 Oct 2026 09:29:32 -0400

UBS analyst Ashwani Verma raised the price target on Incyte (NASDAQ: INCY) to $127.00 (from $113.00) while maintaining a Neutral rating.

The analyst commented, "Heading into YE, the key focus is on the G12D data expected at ESMO & the mCALR 1L MF update at ASH. Our recent KOL checks in the PDAC space increase our confidence in the G12D opportunity. For '734, INCY will share Ph1 data in both 1L PDAC (combining '734 with GeMNabP, mFOLFIRINOX) and 2L+ CRC (monotherapy and cetuximab combo) cohorts. However, heading into ESMO we believe a lot of the core facts are already known and we do not

Incyte (INCY) PT Raised to $127 at UBS, Neutral Rating Maintained

Mon, 05 Oct 2026 09:29:32 -0400

UBS analyst Ashwani Verma raised the price target on Incyte (NASDAQ: INCY) to $127.00 (from $113.00) while maintaining a Neutral rating.

Incyte (INCY) PT Raised to $157 at Stifel

Mon, 05 Oct 2026 05:28:19 -0400

Stifel analyst Stephen Willey raised the price target on Incyte (NASDAQ: INCY) to $157.00 (from $145.00) while maintaining a Buy rating.

The analyst comments "We recently hosted a series of investor meetings with Bill Meury (CEO) and Alexis Smith (VP/IR) ahead of multiple YE26 data catalysts anticipated from the late-stage pipeline at both ESMO (G12Di, PD-1xTGFBR2) and ASH (mCALR). Management’s disclosure framework for these events keeps us constructive over the near-term and we believe INCY’s competitive positioning with a mostly first-in-class pipeline in high-value GI oncology (1L PDAC/mCRC) and hematology indications remains underappreciated here. And while Jakafi LOE (YE28) appropriately dominates

Incyte (INCY) PT Raised to $157 at Stifel

Mon, 05 Oct 2026 05:28:19 -0400

Stifel analyst Stephen Willey raised the price target on Incyte (NASDAQ: INCY) to $157.00 (from $145.00) while maintaining a Buy rating.